The recombinant dna rdna technology industry trends over the past 12 months reveal accelerating collaboration and capital inflow as biopharma firms chase faster cell‑therapy pipelines. In early 2024, ThermoGen partnered with BioMediX to co‑develop a CRISPR‑based gene‑editing platform targeting rare hematologic disorders, leveraging ThermoGen’s high‑throughput screening. Meanwhile, the European Medicines Agency (EMA) issued revised guidance on viral vector safety, shortening clinical‑trial timelines for recombinant vaccines. Simultaneously, GeneCraft completed a $450 million acquisition of NanoVector, expanding its lipid‑nanoparticle portfolio for mRNA delivery. The same quarter, HelixBio launched its first fully‑synthetic plasmid‑free system, promising higher yield and reduced immunogenicity. Venture capital activity surged, with a $200 million Series C round backing SynBioWorks to scale its automated DNA assembly line across Asia. In July 2024, the U.S. FDA introduced a fast‑track designation for recombinant DNA‑based oncology candidates, cutting review periods by up to 30 %. Consumer interest is shifting toward at‑home gene‑therapy kits, prompting startups like DIYGenomics to secure a $75 million seed round for portable CRISPR kits. To meet demand, BioScale announced a new 200,000‑liter bioreactor facility in Singapore, slated to begin production Q1 2025.
